Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Five Prime Therapeutics Inc    FPRX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 06:31pm CET

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that analyses of FGFR2b expression and baseline immune signature in urothelial cancer (UC) samples were featured in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held November 8-12, 2017 in National Harbor, Maryland. A PDF of the poster, "FGFR2b Expression and Baseline Immune Signature to Guide FPA144 Development in Urothelial Cancer," will be made available on the Publications page of the Five Prime website. Five Prime is developing FPA144, an isoform-selective antibody, as a targeted immunotherapy for tumors that overexpress FGFR2b. Five Prime continues to enroll patients in the Phase 1 trial cohort evaluating FPA144 as a treatment for patients with bladder cancer whose tumors overexpress FGFR2b.

“Profiling FGFR2b expression and baseline tumor-associated immune cells could help guide our clinical development strategy for FPA144 in bladder cancer," said Kevin Baker, Ph.D., Senior Vice President, Development Sciences at Five Prime. “Previously we showed in a pre-clinical model with moderate FGFR2b expression, that FPA144 can reprogram the tumor microenvironment making it more inflammatory. In the same studies, we also showed that FPA144 and PD-1 blockade have additive anti-tumor effects.”

Five Prime evaluated FGFR2b expression in 387 archival primary early stage UC samples and previously reported that >10% had overexpression of FGFR2b by immunohistochemistry (IHC) with intensity level of at least 1+. The research team selected 32 archival UC cases with a range of FGFR2b expression (62% were FGFR2b positive) and characterized baseline immune composition in the tumor microenvironment and the relationship with FGFR2b expression to potentially guide FPA144 development in combination with other therapies.

The results from the selected cases suggest that FGFR2b is expressed in all immune subtypes of UCs, but the expression level varies. The highest level of expression is in inflamed and more proliferative UCs. The Company plans to evaluate additional archival UC tissues from patients with more advanced metastatic disease to determine if there is an association of FGFR2b expression with baseline immune signature in late-stage patient tumors.

About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT
Derek Cole
Investor Relations Advisory Solutions
720-785-4497
[email protected]


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FIVE PRIME THERAPEUTICS IN
01/09 FIVE PRIME THERAPEUTICS : Earns IND Milestone Payment Under Immune Checkpoint Pa..
01/08 Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint P..
01/03 FIVE PRIME THERAPEUTICS : Submits Investigational New Drug Application for Novel..
01/03 Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conf..
01/03 FIVE PRIME THERAPEUTICS : Begins Patient Dosing in Trial
01/02 Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase ..
2017 FIVE PRIME THERAPEUTICS : Zai gets Chinese rights to Five Prime's mAb
2017 FIVE PRIME THERAPEUTICS INC : Entry into a Material Definitive Agreement, Financ..
2017 ZAI LAB : Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreeme..
2017 FIVE PRIME THERAPEUTICS : to Present at BMO Capital Markets Prescriptions for Su..
More news
News from SeekingAlpha
2017 FIVE PRIME THERAPEUTICS : Is This A High-Five Investment?
2017 WEEK IN REVIEW : Nearly $2 Billion Late-December Week For China Pharma Deals
2017 Five Prime Therapeutics (FPRX) Investor Presentation - Slideshow
2017 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2017 PREMARKET GAINERS AS OF 9 : 05 am
Financials ($)
Sales 2017 44,3 M
EBIT 2017 -158 M
Net income 2017 -156 M
Finance 2017 305 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 7,45x
Capi. / Sales 2018 8,19x
Capitalization 635 M
Chart FIVE PRIME THERAPEUTICS IN
Duration : Period :
Five Prime Therapeutics In Technical Analysis Chart | FPRX | US33830X1046 | 4-Traders
Technical analysis trends FIVE PRIME THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 63,1 $
Spread / Average Target 187%
EPS Revisions
Managers
NameTitle
Aron M. Knickerbocker President, Chief Executive Officer & Director
Lewis T. Williams Executive Chairman
Marc L. Belsky Chief Financial Officer & Senior Vice President
Luis Borges Senior Vice President-Research
Helen Collins Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
FIVE PRIME THERAPEUTICS INC0.18%635
GILEAD SCIENCES13.04%105 754
VERTEX PHARMACEUTICALS5.41%39 951
REGENERON PHARMACEUTICALS-1.18%39 917
GENMAB13.75%11 762
EXELIXIS, INC.-7.89%8 284